妇科试验常因症状而非疾病本身排除受试者:对Cochrane综述及其组成试验的系统综述
该系统综述检索Cochrane图书馆(2022年2月)中多囊卵巢综合征(PCOS)和子宫内膜异位症综述,纳入干预旨在治疗所有疾病相关症状的综述。共分析13篇PCOS综述中的89项试验和11篇子宫内膜异位症综述中的13项试验。多数试验将 eligibility 限制于具有特定症状的受试者(PCOS 55%,子宫内膜异位症46%),其次为测量和分析并非与所有受试者相关的临床结局(PCOS 38%,子宫内膜异位症31%)。综述因试验所测结局而排除了27%的试验,这些试验在相同疾病患者中评估相同干预。结论:多数妇科试验排除了可能获益的患者或测量了并非与所有受试者相关的结局,作者引入分类法描述异质性症状疾病条件下的试验设计策略。
要点
- PCOS试验中55%、子宫内膜异位症试验中46%将 eligibility 限制于特定症状受试者。
- PCOS试验中38%、子宫内膜异位症试验中31%测量和分析并非与所有受试者相关的结局。
- 综述因试验所测结局排除了27%的评估相同干预的试验。
核心结论
- 多数妇科试验排除了可能从治疗中获益的患者,或测量了并非与所有受试者相关的结局。
- 作者引入分类法以描述异质性症状疾病条件下的试验设计策略。
研究设计与样本
- 系统综述:检索Cochrane图书馆(2022年2月)中多囊卵巢综合征(PCOS)和子宫内膜异位症综述。
- 纳入标准为干预旨在治疗所有疾病相关症状的综述。
- 共纳入13篇PCOS综述中的89项不同试验和11篇子宫内膜异位症综述中的13项试验。
- 记录每项试验所用策略及因该策略直接排除的潜在合格受试者数量,以及每篇综述中因症状经历而被排除的RCT和受试者数量。
主要发现
- 多数试验将 eligibility 限制于具有特定症状的受试者:PCOS为55%,子宫内膜异位症为46%。
- 第二常见策略为测量和分析并非与所有受试者相关的临床结局:PCOS为38%,子宫内膜异位症为31%。
- 综述因试验所测结局排除了27%的试验,这些试验在相同疾病患者中评估相同干预。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify strategies used in recent randomized controlled trials (RCTs) and their associated Cochrane Reviews where patients with the same gynecological condition present with different symptoms but would plausibly benefit from a common intervention. STUDY DESIGN AND SETTING: We searched the Cochrane library (February 2022) for reviews in polycystic ovarian syndrome (PCOS) and endometriosis. Reviews were included if the intervention was intended to treat all condition-specific symptoms. For each trial we recorded the strategy used and the number of potentially eligible participants excluded as a direct result of the chosen strategy. For each review we recorded the numbers of RCTs and participants excluded on the basis of symptoms experienced. RESULTS: There were 89 distinct PCOS trials in 13 reviews, and 13 Endometriosis trials in 11 reviews. Most trials restricted their eligibility to participants with specific symptoms (55% PCOS, 46% endometriosis). The second most common strategy was to measure and analyze clinical outcomes that were not relevant to all participants (38% PCOS, 31% endometriosis). Reviews excluded 27% of trials in participants evaluating the same intervention in participants experiencing the same condition based on the outcomes measured in the trials. CONCLUSION: Most gynecological trials exclude patients who could benefit from treatment or measure outcomes not relevant to all participants. We introduce a taxonomy to describe trial design strategies for conditions with heterogeneous symptoms.
引用
- Stocking K, Watson A, Kirkham JJ, et al. Gynecological trials frequently exclude people based on their symptoms rather than their condition: a systematic review of Cochrane reviews and their component trials. J Clin Epidemiol. 2023. PMID: 37778735. doi:10.1016/j.jclinepi.2023.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。